Exubera filed in Europe; U.S. plans?
This article was originally published in Pharmaceutical Approvals Monthly
Aventis and Pfizer are "working with [FDA] to determine the appropriate timing for submission of the Exubera [NDA] in the U.S.," according to Aventis. The firms announced submission of a marketing authorization application for their inhaled insulin product with the European Medicines Evaluation Agency March 4, for treatment of type 1 and 2 diabetes...
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.